Search results
Lung cancer, with non-small cell lung cancer (NSCLC) being the major type, is the second most common malignancy and the leading cause of cancer-related death globally. Immunotherapy, represented by immune checkpoint inhibitors (ICIs), has been one of the greatest advances in recent years for the treatment of solid tumors including NSCLC.
13 maj 2021 · PDF. Practical Applications. •. Immunotherapy consists of a class of drugs that interact with the immune system to induce cancer cell apoptosis. Monoclonal antibodies against PD-1, PD-L1, and CTLA-4 are the most commonly used immune checkpoint inhibitors for patients with non–small cell lung cancer. •.
20 sty 2021 · Relevance for patients: Immunotherapy has revolutionized the treatment of non-small cell lung cancer patients reaching better survival outcomes in first and second palliative setting and in...
9 lut 2022 · Here, we will summarize the current state of immunotherapy in lung cancer, discuss novel targets, and explore the intersection between DNA repair defects and immunotherapy.
5 sty 2022 · The implementation of immunotherapies with checkpoint inhibitors has substantially improved therapeutic outcomes of patients with advanced or metastatic non–small-cell lung cancer (NSCLC).
14 wrz 2024 · Therefore, the present study sought to examine how the incidence, incidence-based mortality (IBM), and survival changes of lung cancer by all histological types over the past two decades, with a focus on evaluating the possible impact of immunotherapy on patient survival at the population level.
A: Lung cancer immunotherapy by using a tumor-specific vaccine to combat cancer. B: Donor or patient T cells are collected in vitro, followed by the introduction of Chimeric Antigen Receptor (CAR) receptors and mass-produced in the lab to combat cancer.
